Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy shows promise in cancer immunotherapy.
• Challenges with unclear mechanisms impede the widespread clinical use of CAR T-cell therapy.

Purpose of the Study:

• To review the applications of single-cell sequencing technologies in CAR T-cell therapy.
• To explore how single-cell sequencing enhances understanding of CAR T-cell biology, clinical responses, and adverse events.
• To discuss strategies for CAR T-cell therapy development and target selection.

Main Methods:

• Review of recent literature on single-cell sequencing applications in CAR T-cell therapy.
• Analysis of biological characteristics, clinical response mechanisms, and adverse events.
• Examination of strategies for CAR T-cell therapy development and CAR target selection.

Main Results:

• Single-cell sequencing provides high-resolution analysis of cellular heterogeneity and molecular patterns.
• These technologies have significantly advanced the understanding of immunology and oncology in the context of CAR T-cell therapy.
• Applications include characterizing CAR T-cells, elucidating response/adverse event mechanisms, and guiding therapy development.

Conclusions:

• Single-cell sequencing is crucial for dissecting CAR T-cell therapy complexities.
• A multi-omics approach is proposed to guide future research in this field.
• Further research using these technologies will optimize CAR T-cell therapy efficacy and safety.